Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled dose-ranging study of MTPS9579A in refractory chronic spontaneous urticaria
2021-002669-16Phase 2Terminated
- Sponsor
- Genentech
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing MTPS9579A dose-ranging arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in UAS7 at Week 12. Started Dec 2021; status: terminated.
02
Drugs
MTPS9579A
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2021-002669-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002669-16.